Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphomaChava Perry, Irit Avivi, M. Morales et al.|Blood Advances|2021Cited by 170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort StudyRon Ram, Ronen Ben‐Ami, David Hagin et al.|Transplantation and Cellular Therapy|2021Cited by 164